Among them, catumaxomab, one of the first FDA-approved trifunctional Abs, binds CD3 on T cells, epithelial cell adhesion molecule (EpCAM) overexpressed on human adenocarcinomas, and the Fc receptors on other immune cells.48 The gene discussed is EPCAM; the disease is adenocarcinoma.